摘要
To the Editor:Since the first IgE monoclonal antibody was approved by the Food and Drug Administration in the USA in 2003,at least 14 kinds of targeted drugs are in the clinical application or pre-clinical trials.The two monoclonal antibodies targeting IgE are omalizumab and ligelizumab.Four drugs targeting interleukin 4(IL-4)or IL-4R are pascolizumab,pitrakinra,altrakincept,and dupilumab.Three monoclonal antibodies targeting IL-5/IL-5R are mepolizumab,reslizumab,and benralizumab.Two monoclonal antibodies targeting IL-13 are lebrikizumab and tralokinumab.The monoclonal antibody targeting thymic stromal lymphopoietin(TSLP)is tezepelumab.Th2 cytokine inhibitor is mesylate.These targeted drugs have achieved good results,but most of them are still in the pre-clinical stage.This article reviews the history,marketing situation,indications,contraindications,efficacy,and safety of these targeted drugs.
基金
the Major Project of Hainan Province(No.ZDKJ2016008)
the Key Project of Social Development in Hainan Province and Matching Fund from Sanya City of Hainan Province(No.ZDYF2016127)
the National Natural Science Foundation of China(Nos.81371074,81670901).
